Kopin Corporation (KOPN)
NASDAQ: KOPN
· Real-Time Price · USD
1.47
-0.05 (-3.29%)
At close: May 16, 2025, 3:59 PM
1.43
-2.72%
Pre-market: May 19, 2025, 05:13 AM EDT
Kopin Revenue Breakdown
| Period Ending | Dec 28, 2024 | Dec 30, 2023 | Dec 31, 2022 | Dec 25, 2021 | Dec 29, 2018 | Dec 30, 2017 |
|---|---|---|---|---|---|---|
| Consumer Revenue | 25K | 573K | 1.5M | 1.87M | 7.48M | 13.58M |
| Consumer Revenue Growth | -95.64% | -61.72% | -19.99% | -75.00% | -44.91% | n/a |
| Defense Revenue | 41.25M | 22.61M | 24.78M | 18.18M | n/a | n/a |
| Defense Revenue Growth | +82.40% | -8.74% | +36.30% | n/a | n/a | n/a |
| Industrial Revenue | 2.2M | 2.74M | 6.14M | 9.71M | n/a | n/a |
| Industrial Revenue Growth | -19.59% | -55.41% | -36.81% | n/a | n/a | n/a |
| License and Royalties Revenue | 442K | 1M | n/a | 1.11M | n/a | n/a |
| License and Royalties Revenue Growth | -55.89% | n/a | n/a | n/a | n/a | n/a |
| Medical Revenue | 103K | 13.46M | n/a | 14.67M | n/a | n/a |
| Medical Revenue Growth | -99.23% | n/a | n/a | n/a | n/a | n/a |
| Other Product Revenue | 320K | n/a | n/a | n/a | n/a | n/a |
| Other Product Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue | 6M | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 29, 2025 | Dec 28, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 30, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Sep 24, 2022 | Jun 25, 2022 | Mar 26, 2022 | Dec 25, 2021 | Sep 25, 2021 | Jun 26, 2021 | Mar 27, 2021 | Dec 26, 2020 | Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | Dec 28, 2019 | Sep 28, 2019 | Jun 29, 2019 | Mar 30, 2019 | Dec 29, 2018 | Sep 29, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 30, 2017 | Sep 30, 2017 | Jul 1, 2017 | Apr 1, 2017 | Dec 31, 2016 | Sep 24, 2016 | Jun 25, 2016 | Mar 26, 2016 | Dec 26, 2015 | Sep 26, 2015 | Jun 27, 2015 | Mar 28, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | n/a | 3.14M | 5.21M | 7.27M | 7.23M | 5.93M | 4.8M | 6.47M | 4.65M | 4.85M | 4.32M | 4.33M | 4.46M | 4.12M | 4.04M | 4.04M | 5.91M | 2.4M | 3.08M | 2.91M | 3.43M | 4.53M | 5.13M | 5.38M | 6.28M | 6.2M | 7.17M | 6.91M | 6.93M | 4.35M | 5.34M | 5.2M | 5.64M | 4.94M | 3.96M | 4.28M | 3.76M | 4.08M | 4.56M | 5.11M | 4.39M |
| Selling, General, and Administrative Revenue Growth | -100.00% | -39.73% | -28.36% | +0.50% | +21.97% | +23.56% | -25.79% | +39.11% | -4.22% | +12.33% | -0.17% | -3.07% | +8.42% | +2.03% | -0.12% | -31.58% | +145.90% | -22.01% | +5.85% | -15.23% | -24.20% | -11.74% | -4.57% | -14.44% | +1.34% | -13.48% | +3.65% | -0.26% | +59.19% | -18.54% | +2.78% | -7.82% | +14.25% | +24.66% | -7.50% | +13.86% | -7.86% | -10.47% | -10.76% | +16.46% | n/a |
| Research and Development Revenue | 1.24B | 3.1M | 2.6M | 1.84M | 2.1M | 2.24M | 3.09M | 3.13M | 2.31M | -5.61M | 3.44M | 5.15M | 5.41M | 5.23M | 3.75M | 3.89M | 3.56M | 4.39M | 2.72M | 2.22M | 2.34M | 2.66M | 2.39M | 3.33M | 4.97M | 3.87M | 4.6M | 4.53M | 4.45M | 4.67M | 5.25M | 4.68M | 4.28M | 3.76M | 4.12M | 4.12M | 4.04M | 3.88M | 4.01M | 4.88M | 4.86M |
| Research and Development Revenue Growth | +39817.09% | +19.31% | +41.15% | -12.43% | -6.33% | -27.42% | -1.35% | +35.47% | -141.23% | -262.94% | -33.12% | -4.87% | +3.36% | +39.48% | -3.46% | +9.06% | -18.89% | +61.76% | +22.27% | -5.07% | -12.13% | +11.43% | -28.25% | -32.95% | +28.40% | -15.89% | +1.62% | +1.67% | -4.59% | -11.19% | +12.30% | +9.26% | +13.97% | -8.88% | +0.09% | +1.97% | +4.15% | -3.23% | -17.93% | +0.49% | n/a |